Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Bio-Path Holdings Reports Full Year 2024 Financial Results
Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients [Yahoo! Finance]
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients